Rifampicin susceptibility discordance between Xpert MTB/RIF G4 and Xpert Ultra before MDRT-TB treatment initiation: a case report from Uganda

Willy Ssengooba; Kevin Komakech; Sharon Namiiro; Henry Byabajungu; Joanitah Nalunjogi; Winceslaus Katagira; Ivan Kimuli; Moses L. Joloba; Susan Adakun; Lydia Nakiyingi; Gabriela Torrea; Bruce J. Kirenga

doi:10.1016/j.jctube.2021.100286

Rifampicin susceptibility discordance between Xpert MTB/RIF G4 and Xpert Ultra before MDRT-TB treatment initiation: a case report from Uganda

Willy Ssengooba, Kevin Komakech, Sharon Namiiro, Henry Byabajungu, Joanitah Nalunjogi, Winceslaus Katagira, Ivan Kimuli, Moses L. Joloba, Susan Adakun, Lydia Nakiyingi, Gabriela Torrea, Bruce J. Kirenga

Mycobacteriology

Research output: Contribution to journal › A1: Web of Science-article › peer-review

27 Downloads (Pure)

Abstract

Tuberculosis (TB) resistance to rifampicin, the most powerful drug leads to increase in mortality. Globally, half a million new patients develop such resistant TB each year, coupled with both inappropriate diagnosis and treatment initiation.

We report a case of rifampicin resistant Mycobacterium tuberculosis whose rifampicin resistance was missed by Xpert MTB/RIF Assay G4 but detected by the Xpert MTB/RIF Ultra assay at different time points leading to increased delays for MDR-TB treatment initiation at Mulago Hospital, Kampala, Uganda. Our case report compels greater urgency in accelerating the transition to the newer assay, Ultra, to benefit from higher sensitivity of rifampicin resistance detection.

Original language	English
Article number	100286
Journal	Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
Volume	25
Number of pages	5
ISSN	2405-5794
DOIs	https://doi.org/10.1016/j.jctube.2021.100286
Publication status	Published - 2021

Keywords

XpertMTB/RIF
G4
ULTRA
Rifampicin
Discordance
MYCOBACTERIUM-TUBERCULOSIS
RESISTANCE

Access to Document

10.1016/j.jctube.2021.100286Licence: CC BY-NC-ND

2021jcto100286Final published version, 4.62 MBLicence: CC BY-NC-ND

Cite this

Ssengooba, W., Komakech, K., Namiiro, S., Byabajungu, H., Nalunjogi, J., Katagira, W., Kimuli, I., Joloba, M. L., Adakun, S., Nakiyingi, L., Torrea, G., & Kirenga, B. J. (2021). Rifampicin susceptibility discordance between Xpert MTB/RIF G4 and Xpert Ultra before MDRT-TB treatment initiation: a case report from Uganda. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 25, Article 100286. https://doi.org/10.1016/j.jctube.2021.100286

@article{db56455636a849e7bd7a20a27f7058d8,

title = "Rifampicin susceptibility discordance between Xpert MTB/RIF G4 and Xpert Ultra before MDRT-TB treatment initiation: a case report from Uganda",

abstract = "Tuberculosis (TB) resistance to rifampicin, the most powerful drug leads to increase in mortality. Globally, half a million new patients develop such resistant TB each year, coupled with both inappropriate diagnosis and treatment initiation.We report a case of rifampicin resistant Mycobacterium tuberculosis whose rifampicin resistance was missed by Xpert MTB/RIF Assay G4 but detected by the Xpert MTB/RIF Ultra assay at different time points leading to increased delays for MDR-TB treatment initiation at Mulago Hospital, Kampala, Uganda. Our case report compels greater urgency in accelerating the transition to the newer assay, Ultra, to benefit from higher sensitivity of rifampicin resistance detection.",

keywords = "XpertMTB/RIF, G4, ULTRA, Rifampicin, Discordance, MYCOBACTERIUM-TUBERCULOSIS, RESISTANCE",

author = "Willy Ssengooba and Kevin Komakech and Sharon Namiiro and Henry Byabajungu and Joanitah Nalunjogi and Winceslaus Katagira and Ivan Kimuli and Joloba, {Moses L.} and Susan Adakun and Lydia Nakiyingi and Gabriela Torrea and Kirenga, {Bruce J.}",

note = "FTX; DOAJ; (CC BY-NC-ND 4.0)",

year = "2021",

doi = "10.1016/j.jctube.2021.100286",

language = "English",

volume = "25",

journal = "Journal of Clinical Tuberculosis and Other Mycobacterial Diseases",

issn = "2405-5794",

publisher = "Elsevier",

}

Ssengooba, W, Komakech, K, Namiiro, S, Byabajungu, H, Nalunjogi, J, Katagira, W, Kimuli, I, Joloba, ML, Adakun, S, Nakiyingi, L, Torrea, G & Kirenga, BJ 2021, 'Rifampicin susceptibility discordance between Xpert MTB/RIF G4 and Xpert Ultra before MDRT-TB treatment initiation: a case report from Uganda', Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, vol. 25, 100286. https://doi.org/10.1016/j.jctube.2021.100286

Rifampicin susceptibility discordance between Xpert MTB/RIF G4 and Xpert Ultra before MDRT-TB treatment initiation: a case report from Uganda. / Ssengooba, Willy; Komakech, Kevin; Namiiro, Sharon et al.
In: Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, Vol. 25, 100286, 2021.

Research output: Contribution to journal › A1: Web of Science-article › peer-review

TY - JOUR

T1 - Rifampicin susceptibility discordance between Xpert MTB/RIF G4 and Xpert Ultra before MDRT-TB treatment initiation: a case report from Uganda

AU - Ssengooba, Willy

AU - Komakech, Kevin

AU - Namiiro, Sharon

AU - Byabajungu, Henry

AU - Nalunjogi, Joanitah

AU - Katagira, Winceslaus

AU - Kimuli, Ivan

AU - Joloba, Moses L.

AU - Adakun, Susan

AU - Nakiyingi, Lydia

AU - Torrea, Gabriela

AU - Kirenga, Bruce J.

N1 - FTX; DOAJ; (CC BY-NC-ND 4.0)

PY - 2021

Y1 - 2021

N2 - Tuberculosis (TB) resistance to rifampicin, the most powerful drug leads to increase in mortality. Globally, half a million new patients develop such resistant TB each year, coupled with both inappropriate diagnosis and treatment initiation.We report a case of rifampicin resistant Mycobacterium tuberculosis whose rifampicin resistance was missed by Xpert MTB/RIF Assay G4 but detected by the Xpert MTB/RIF Ultra assay at different time points leading to increased delays for MDR-TB treatment initiation at Mulago Hospital, Kampala, Uganda. Our case report compels greater urgency in accelerating the transition to the newer assay, Ultra, to benefit from higher sensitivity of rifampicin resistance detection.

AB - Tuberculosis (TB) resistance to rifampicin, the most powerful drug leads to increase in mortality. Globally, half a million new patients develop such resistant TB each year, coupled with both inappropriate diagnosis and treatment initiation.We report a case of rifampicin resistant Mycobacterium tuberculosis whose rifampicin resistance was missed by Xpert MTB/RIF Assay G4 but detected by the Xpert MTB/RIF Ultra assay at different time points leading to increased delays for MDR-TB treatment initiation at Mulago Hospital, Kampala, Uganda. Our case report compels greater urgency in accelerating the transition to the newer assay, Ultra, to benefit from higher sensitivity of rifampicin resistance detection.

KW - XpertMTB/RIF

KW - G4

KW - ULTRA

KW - Rifampicin

KW - Discordance

KW - MYCOBACTERIUM-TUBERCULOSIS

KW - RESISTANCE

U2 - 10.1016/j.jctube.2021.100286

DO - 10.1016/j.jctube.2021.100286

M3 - A1: Web of Science-article

C2 - 34816021

SN - 2405-5794

VL - 25

JO - Journal of Clinical Tuberculosis and Other Mycobacterial Diseases

JF - Journal of Clinical Tuberculosis and Other Mycobacterial Diseases

M1 - 100286

ER -

Rifampicin susceptibility discordance between Xpert MTB/RIF G4 and Xpert Ultra before MDRT-TB treatment initiation: a case report from Uganda

Abstract

Keywords

Access to Document

Fingerprint

Cite this